Lemborexant

Pre-clinicalCompleted
1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sleep Initiation and Maintenance Disorders

Conditions

Sleep Initiation and Maintenance Disorders

Trial Timeline

Oct 17, 2020 → Mar 17, 2022

About Lemborexant

Lemborexant is a pre-clinical stage product being developed by Eisai for Sleep Initiation and Maintenance Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT04573556. Target conditions include Sleep Initiation and Maintenance Disorders.

What happened to similar drugs?

20 of 20 similar drugs in Sleep Initiation and Maintenance Disorders were approved

Approved (20) Terminated (2) Active (0)
Zolpidem MR + EstazolamAstellas PharmaApproved
Zolpidem MR + Zolpidem IRAstellas PharmaApproved
Lemborexant + PlaceboEisaiApproved
Eszopiclone + Placebo controlSumitomo PharmaApproved
Eszopiclone + Fluoxetine + PlaceboSumitomo PharmaApproved
Lunesta + Placebo controlSumitomo PharmaApproved
LunestaSumitomo PharmaApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT05594589Phase 2Completed
NCT04890561Phase 1Completed
NCT04555733Phase 1Completed
NCT04573556Pre-clinicalCompleted
NCT03443063Phase 1Completed
NCT03440424Phase 1Completed

Competing Products

20 competing products in Sleep Initiation and Maintenance Disorders

See all competitors